U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C4H4FN3O
Molecular Weight 129.0925
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FLUCYTOSINE

SMILES

NC1=NC(=O)NC=C1F

InChI

InChIKey=XRECTZIEBJDKEO-UHFFFAOYSA-N
InChI=1S/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9)

HIDE SMILES / InChI

Description

Flucytosine (5-flucytosine, Ancobon) is an antifungal agent used for treatment of serious fungal infections caused by Candida or Cryptococcus. A fluorinated cytosine analog it was originally developed as an anti-tumor agent, but was found to be non-effective against tumors. Monotherapy with 5-FC is limited because of the frequent development of pathogens resistance. It is often used in in combination with amphotericin B. The severe side effects of 5-flucytosine include hepatotoxicity and bone-marrow depression. 5-fluorocytosine is a prodrug to the cytotoxic compound 5-fluorouracil. Although the exact mode of action is unknown, it has been proposed that flucytosine acts directly on fungal organisms by competitive inhibition of purine and pyrimidine uptake and indirectly by intracellular metabolism to 5-fluorouracil. Flucytosine is taken up by fungal organisms via the enzyme cytosine permease. Inside the fungal cell, flucytosine is rapidly converted to fluorouracil by the enzyme cytosine deaminase. Fluorouracil exerts its antifungal activity through the subsequent conversion into several active metabolites, which inhibit protein synthesis by being falsely incorporated into fungal RNA or interfere with the biosynthesis of fungal DNA through the inhibition of the enzyme thymidylate synthetase.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
ANCOBON
Curative
ANCOBON
Curative
ANCOBON
Curative
ANCOBON
Curative
ANCOBON

Cmax

ValueDoseCo-administeredAnalytePopulation
75 μg/mL
37.5 mg/kg 4 times / day multiple, oral
FLUCYTOSINE serum
Homo sapiens
57.3 mg/L
1500 mg single, oral
FLUCYTOSINE serum
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
435 mg × h/L
1500 mg single, oral
FLUCYTOSINE serum
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
8.11 h
1500 mg single, oral
FLUCYTOSINE serum
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
96.6%
37.5 mg/kg 4 times / day multiple, oral
FLUCYTOSINE serum
Homo sapiens

Doses

AEs

PubMed

Sample Use Guides

In Vivo Use Guide
The usual dosage is 50 to 150 mg/kg/day administered in divided doses at 6- hour intervals.
Route of Administration: Oral
In Vitro Use Guide
MIC ≤4 ug/ml for susceptible pathogen